Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
Business Wire•04/11/2026•07:00 ET
0
Key Highlights
- ➤Panorama Phase 3 demonstrated statistically significant improvements in adults with generalized anxiety disorder
- ➤Emerge Phase 3 produced positive topline results in major depressive disorder
- ➤Voyage Phase 3 produced positive topline results in generalized anxiety disorder
- ➤Safety data from three DT120 Phase 3 studies will be presented
- ➤DT120 received FDA Breakthrough Therapy designation for generalized anxiety disorder and major depressive disorder
Expert Statements
Dan Karlin, Chief Medical Officer, Definium Therapeutics
“We look forward to sharing new data from our DT120 program with the psychiatric community at the NEI Fall Congress. These presentations will add to the growing body of evidence from our clinical development program in GAD and MDD, and support continued clinical assessment of DT120’s potential role in treating these conditions.”
Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
First-ever comprehensive presentation of DT120 clinical program to date including positive topline data from Panorama, Emerge and Voyage Phase 3 studies
Get started
Create a free account to read the full story.